Stocktoria
Tango Therapeutics, Inc. TNGX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-09-03
Tango Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -178.4% | -346.1% | -312.6% | -446.8% | -157.1% |
| Net margin | -162.9% | -309.7% | -278.5% | -435.1% | -157.2% |
| FCF margin | -224.3% | -314.4% | -327.2% | -469.7% | -165.7% |
| Return on assets | -25.5% | -41.2% | -25.3% | -24.8% | -11.6% |
| Return on equity | -29.3% | -65.3% | -40.2% | -43.4% | -16.9% |
| Current ratio | 16.32 | 6.98 | 7.54 | 6.76 | 12.10 |
| Revenue growth | 48.3% | 15.2% | 46.9% | -32.9% | 383.8% |
Source: SEC EDGAR filings · CIK 0001819133 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.